www.fdanews.com/articles/197333-puretech-selects-experimental-covid-19-treatment-for-human-trials
PureTech Selects Experimental COVID-19 Treatment for Human Trials
May 29, 2020
PureTech Health said it will begin human trials on an experimental treatment for respiratory complications following recovery from COVID-19 infections.
The treatment, LYT-100 (deupirfenidone), is an analog of the pulmonary fibrosis treatment pirfenidone. It is designed to reduce, delay or prevent the lung dysfunction that has been documented in COVID-19 patients, including in those who have recovered.
The company began a phase 1 trial of the treatment in March, testing its safety and tolerability in healthy participants. It plans to begin further trials of the treatment in the third quarter of this year.